( TSX: BMR TORONTO July 10 2007 /PRNew...)Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings,Health

TORONTO, July 10, 2007 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that new research published by an independent team in Basel, Switzerland validates tenascin as an important molecular target for the development of new treatments for glioblastoma multiforme (GBM).

The researchers identified that the loss of NOTCH2 gene positively predicts survival in subgroups of human glial brain tumors (http://www.plosone.org/doi/pone.0000576) and these markers are highly predictive of survival in subgroups of GBM patients. Ongoing work at the Laboratory of Molecular Neuro-Oncology, Department of Research, University Hospital, Basel, Switzerland has reported that NOTCH2 upregulates tenascin and that high tenascin-C expression reduces the prognosis of disease-free survival in patients with some cancers (Cancer Lett.2006 Dec 8;244(2):143-63. Epub 2006).

Tenascin-C is an extracellular matrix protein that is highly expressed in the microenvironment of glioblastoma and is the molecular target for Bradmer's lead clinical candidate, Neuradiab.

"This new research confirms that Neuradiab is targeting a key marker in the progression of GBM that is also expressed in virtually all GBM cases. This is important because selectively targeting a widely expressed marker is critical to developing a broadly effective GBM therapy," said Dr. Alan Ezrin, Chief Operating Officer of Bradmer. "The results of this new article add to a growing base of recent scientific research which supports the rationale for targeting tenascin-C with a local mechanism of action in the GBM setting. This ongoing research complements the profile and mechanism of action of Neuradiab. In a series of Phase I and Phase II trials, Neuradiab has demonst
'"/>